Postmenopozal Kadınlarda Endometrial Kalınlığın Seks Hormonları ve Metabolik Parametrelerle İlişkisi

Amaç: Bu çalışma postmenopozal kadınlarda seks steroidleri ve metabolik parametreler ileendometrial kalınlık arasındaki bağlantıyı araştırmak amacıyla planlandıGereç ve Yöntem: 2010-2012 yılları arasında prospektif bir çalışmaya dahil olan hastalarınverileri değerlendirildi. Postmenopozal hastaların endometrial kalınlık ölçümleri, hormonal vemetabolik parametreleri ile karşılaştırıldı.Bulgular: Çalışmaya 54 hasta dahil edildi. Endometrial kalınlığı 5mm'nin altında olan olgulardaortalama FSH değeri 83.8±27.7 mIU/ml, endometrial kalınlığı 5mm ve üzerinde olan olgulardaise ortalama FSH değeri 52.4±16.7mIU/ml olarak bulunmuştur (p=0.043). Endometrial kalınlıkile seks steroidleri, vücut kitle indeksi (VKİ) ve metabolik parametreler arasında bir ilişkisaptanmamıştır.Sonuç: Postmenopozal olgularda endometrial kalınlık artışında rol oynayabilecek biyokimyasalve hormonal parametre bulunmamıştır. Daha büyük hasta grupları ile çalışmak sonuçlarıdeğiştirebilir

Anahtar Kelimeler:

Endometrial kalınlık, seks steroidleri, kardiovasküler hastalık

Relationship of Endometrial Thickness with Metabolic Parameters and Sex-steroids in Postmenopausal Women

Purpose: The aim of this study was to understand the relationship between endometrialthickness and metabolic parameters and sex-steroids in postmenopausal women.Methods: We used data of patients attending a prospective study between 2010 and 2012. Wecompared endometrial thickness of postmenopausal women with hormonal and metabolicparameters.Results: We included 54 patients in this study. Mean FSH level of patients with an endometrialthickness

Keywords:

Endometrial thickness, sex-steroids, cardiovascular disease.,

PDF

___

Simpson ER. Aromatization of androgens in women: current concepts and findings. Fertil Steril 2002; 77: 6-10.

Makimura H, Wei J, Dolan-Lobby SE, Ricchiuti V, Grinspoon S. Retinol-Binding Protein levels are increased in association with gonadotropin levels in healthy women. Metabolism 2009; 58(4): 479-87.

Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, et al.Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr Relat Cancer 2008; 15:.485-97.

Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women Int J Cancer 2004; 108: 425-32.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin- like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 921-9.

Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews 2004; 4: 579-91.

Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335: 640-9.

Beral V. On Behalf of Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-51.

Yıldırım M, Bozkurt N, Kurdoglu M, Taskiran C, Öktem M, Dilek KU. Histopathologic findings in women with postmenopausal bleeding: implication for endometrial thickness and circulating levels of sex steroid hormones. Arch Gynecol Obstet 2007; 276(4): 305-10.

Arıkan İİ, Barut A, Arıkan D, Harma M, Harma Mİ, Bozkurt S. Comparison of serum androgens and endometrial thickness in obese and non-obese postmenpausal women. J Turkish- German Gynecol Assoc 2010; 11: 149-51.

Serin SI, Ozcelik B, Basbug M, Ozsahin O, Yılmazsoy A, Erez R. Effects of hypertension and obesity on endometrial thickness. Eur J Obstet Gynecol Reprod Biol 2003; 109: 72- 5.

Weinberg ME, Manson JE, Buring JE, Cook NR, Seely EW, Ridker PM, et al. Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women Metab Clin Exp 2006; 55: 1473-80.

Tchernof A, Despres JP. Sex steroid hormones, sex hormone- binding globulin, and obesity in men and women. Horm Metab Res 2000; 32: 526-36.

Sit AS, Modugno F, Hill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol Biomarkers Prev 2004; 13: 1459-65.

Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Preven 2002; 11: 1531-43.

Strauss DS. Growth stimulatory actions of insulin in vitro and in vivo. Endocrine Reviews. 1984; 5: 356-69.

Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-66.

Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.

Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005; 117: 104-11.

ZhaoY, Nichols JE, Bulun SE, Mendelson CR, Simpson ER. Aromatase p450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose- specific promoter. Journal of Biological Chemistry 1995; 270: 16449-57.

Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone non-users. Cancer Epidemiol Biomarkers Prev 2011; 20(5): 971-7.

Zang H, Sahlin L, Masironi B, Erikson E, Linden Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 2169-75.

Zang H, Sahlin L, Masironi B, Hirschberg AL. Effects of testosterone and estrogen on the distribution of sex hormone receptors in the endometrium of postmenopausal women Menopause 2008; 15(2): 233-9.

Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, et al. 17beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006; 248: 136-40.